1 **TITLE**: Creation of a ustekinumab external control arm for Crohn's disease using electronic
2 health records data: a pilot study
3

AUTHORS: Vivek A. Rudrapatna MD PhD[1,2], Yao-Wen Cheng MD[1], Colin Feuille MD[1], Arman
Mosenia MSE[3], Jonathan Shih BS[4], Yongmei Shi PhD[2], Olivia Roberson PhD[1], Benjamin Rubin
PhD[1], Atul J. Butte MD PhD[2,5], Uma Mahadevan MD[1], Nicholas Skomrock MAS MS[6], Ngozi
Erondu MD PhD[6], Christel Chehoud PhD[6], Saquib Rahim MD MBA[6], David Apfel MBA[6], Mark
Curran PhD[6], Najat S. Khan PhD[6], Christopher O'Brien MD PhD[6], Natalie Terry MD PhD[6],
Benjamin D Martini MD MBA[6]
10
AFFILIATIONS:
1. Division of Gastroenterology, Department of Medicine, University of California, San
Francisco, San Francisco, CA
2. Bakar Computational Health Sciences Institute, University of California, San Francisco, San
Francisco, CA
3. School of Medicine, University of California, San Francisco, San Francisco, CA
4. Department of Neurology, University of California, San Francisco, San Francisco, CA
5. Department of Pediatrics, University of California, San Francisco, San Francisco, CA
6. Janssen Research and Development LLC, Spring House, PA 19477
20
GUARANTOR: Vivek Rudrapatna. UCSF Bakar Institute, Box 2933, 490 Illinois Street, Floor 2,
San Francisco, CA 94143. Email: vivek.rudrapatna@ucsf.edu

AUTHOR CONTRIBUTIONS: VAR and BDM conceived the study. VAR designed the study
protocol and analysis plan. VAR, YC, CF, AM, JS performed data collection. VAR and YS
analyzed the raw data and reported the results. VAR, AJB, UM, NS, NE, CC, SR, DA, MC, CO,
NT, and BDM interpreted the data and oversaw the study. OR and BR performed project
management. VAR drafted the manuscript. All authors critically edited the manuscript.

FINANCIAL SUPPORT: Research reported in this publication was supported by Janssen
Research and Development LLC, the UCSF Bakar Computational Health Sciences Institute,
and the National Center for Advancing Translational Sciences, National Institutes of Health,
through UCSF-CTSI Grant Number UL1 TR001872. Its contents are solely the responsibility of
the authors and do not necessarily represent the official views of the NIH. None of the study
sponsors had any influence over the data interpretation or conclusions from this study.

POTENTIAL COMPETING INTERESTS: NS, NE, CC, SR, DA, MC, NSK, CO, NT, and BDM
are employees of Janssen Pharmaceuticals, a for-profit entity that owns all rights to the drug
ustekinumab. UM is a consultant for Janssen Pharmaceuticals. No other competing interests
relevant to this publication exist.
KEYWORDS: external control arm, real-world evidence, electronic health records, clinical
informatics, Crohn's disease, ustekinumab
WORD COUNT: 2994

ABSTRACT
42
43   **Objectives**:
44   The use of external control arms to support claims of efficacy and safety is growing in interest
45   among drug sponsors and regulators. However, experience with performing these kinds of
46   studies for complex, immune-mediated diseases is limited. We sought to establish a method for
47   creating an external control arm for Crohn's disease.
48
Methods:
We queried electronic health records databases and screened records at the University of
California, San Francisco to identify patients meeting the major eligibility criteria of TRIDENT, a
concurrent trial involving ustekinumab as a reference arm. Timepoints were defined to balance
the tradeoff between missing disease activity and bias. We compared two imputation models by
their impacts on cohort membership and outcomes. We compared the results of ascertaining
disease activity using structured data algorithms against manual review. We used these data to
estimate ustekinumab's real-world effectiveness.
57
Results:
Screening identified 183 patients. 30% of the cohort had missing baseline data. Two imputation
models were tested and had similar effects on cohort definition and outcomes. Algorithms for
ascertaining non-symptom-based elements of disease activity were similar in accuracy to
manual review. The final cohort consisted of 56 patients. 34% of the cohort was in steroid-free
clinical remission by week 24.
64
65   **Conclusions**:
66   Differences in the timing and goals of real-world encounters as compared to controlled studies
67   directly translate into significant missing data and lost sample size. Efforts to improve real-world
68   data capture and better align trial design with clinical practice may enable robust external
69   control arm studies and improve trial efficiency.
70
71

STUDY HIGHLIGHTS

WHAT IS KNOWN:
- External control arm studies are receiving growing interest from drug sponsors and regulators as a potential source of real-world evidence
- However, the feasibility and robustness of this approach is currently limited
- Ustekinumab is an FDA-approved treatment of moderately to severely active Crohn's disease

WHAT IS NEW HERE:
- We derived a retrospective cohort of patients designed to resemble the participants of TRIDENT, a concurrent phase 2b trial using ustekinumab as a reference arm
- EHR structured data algorithms may be an accurate and less laborious alternative to manual abstraction of non-symptom-based components of the Crohn's Disease Activity Index
- Real-world practice differs from controlled studies in important ways, including the treatment goals and the timing of encounters
- These differences can pose challenges to the feasibility of external control arm studies, and must be addressed to enable this novel study design
- The methods, data, and code used in this pilot study are shared here for reproducibility and enhancement by others

INTRODUCTION:

The term *external control arm* (ECA) commonly refers to the use of retrospective cohorts to estimate treatment effects by indirect comparison to other cohorts, including those in interventional trials. Recent years have seen a growing interest in this approach with regulatory bodies like the FDA evaluating the use of these data to support claims of treatment efficacy and safety[1,2]. ECAs have some advantages over conventional randomized trials, including lowering the cost of executing trials, greater feasibility for rare diseases, smaller patient populations, or situations involving strong treatment preferences (lack of clinical equipoise)[3].

Despite this interest, experience in the conduct of ECAs remains limited. To date, most ECAs with regulatory intent have occurred in the space of oncology and rare diseases[3]. These are contexts where treatment paradigms and outcome measures are relatively well-defined, and thus may align well with prospective study designs. However, the feasibility and robustness of ECAs for more common and complex diseases such as inflammatory bowel disease (IBD) remain unknown. There is an unmet need to better understand ECAs and evaluate their viability as an alternative or supplement to prospective trials, which continue to grow in expense and remain challenging to recruit for.

Our own prior work has used electronic health records (EHR) data to estimate the effectiveness of tofacitinib for treating IBD[4]. While this study suggested that EHR data may be useful for this purpose, it was conducted on a cohort whose baseline characteristics substantially differed from the cohorts under study in the pre-approval trials of this drug.

The primary objective of this pilot study was to define and evaluate a method for creating an external control arm for Crohn's disease. We sought to derive a real-world patient cohort matching the ustekinumab arm of TRIDENT, a concurrent phase 2b trial[5]. Secondary objectives included 1) to evaluate the use of EHR algorithms as an alternative to manual ascertainment of some disease activity variables, 2) to assess the robustness of imputation methods for handling missing data, and 3) to assess ustekinumab's effectiveness.

METHODS:

Eligibility: Four inclusionary and seven exclusionary criteria were adapted from the TRIDENT protocol and retrospectively applied to patients at UCSF who received ustekinumab as part of the standard of care (Supplemental Methods). These criteria select for adults with a Crohn's Disease Activity Index (CDAI) between 220 and 450 and who were stably exposed to other treatments for Crohn's disease.

All major criteria from TRIDENT were applied except for the exclusion of patients with recent exposure to tumor necrosis factor inhibitors (8 weeks) and integrin inhibitors (16 weeks). This decision was undertaken for two reasons: 1) real-world patients who fail to benefit from one biologic are typically switched to another with minimal delay to avoid the risk of a flare, and 2) patients who sustained long biologic washout periods without being hospitalized or meeting other exclusionary criteria tend to have a lower disease severity and thus tended to be excluded due to a low baseline CDAI.

Cohort identification: Cohort identification proceeded in six sequential phases.

Phase 1: Using a database of structured EHR data at the University of California, San Francisco (UCSF; 2012-2020), patient records were queried to find those with a medication order for

145 ustekinumab and a Crohn's disease diagnosis code (ICD-9-CM 555*; ICD-10-CM K50*)
146 anywhere in their care timeline.
147
148 Phase 2: Eligible records were then divided among four trained chart abstractors for additional
149 manual screening. Chart abstraction was performed under the supervision of the principal
150 investigator using a pre-defined protocol (Supplemental Methods).
151
152 Initial manual screening was performed to identify patients meeting all inclusion and exclusion
153 criteria except for that pertaining to the baseline CDAI. The process of manual abstraction
154 included confirmation of the informatics-based criteria used for initial screening (i.e. confirmation
155 of the diagnosis, treatment with ustekinumab, etc.).
156
Phase 3: Patients who met all study criteria prior to the assessment of the baseline CDAI were
identified. From this cohort, the baseline patient-reported outcome elements of the CDAI
(abdominal pain, diarrhea, wellbeing; PRO3) were abstracted using a time window of up to 16
weeks prior to the date of the first dose of ustekinumab. The data were analyzed to empirically
define the baseline period. This corresponded to the narrowest window of time prior to week 0
that was not associated with a substantial increase in missing data.
163
164 Phase 4: The non-PRO3 elements of the CDAI were abstracted by two methods: manual
165 abstraction and informatics criteria (Supplemental Methods). This process was done by one of
166 the four chart abstractors, corresponding to roughly one quarter of the still eligible cohort. All
167 non-PRO3 CDAI elements were abstracted at the baseline period (week -12 to 0) and
168 compared to the informatic approach.
169
170 Manual abstraction was performed on a subset of these variables at post-baseline time periods
171 to assess the accuracy of informatics-based ascertainment across time. These variables
172 included the use of antidiarrheals or opiates (binary), the use of steroids (binary), and
173 hematocrit (numeric). Post-baseline time periods corresponded to the times of the primary and
174 secondary endpoints of TRIDENT.
175
Phase 5: Informatics-based criteria were used to ascertain all non-PRO3 CDAI elements at the
baseline period among the 183 patients (25% of the initial cohort) who met all other criteria.
Given missing CDAI elements at baseline, imputation was required to determine which
individuals met the baseline CDAI requirement and thus could be confirmed as members of the
cohort. Two random forest-based imputation routines (*MissForest*, *MissRanger*) were used to
assess the sensitivity of cohort membership to the choice of imputation model.
182
183 Phase 6: The *MissForest* algorithm was used to finalize cohort membership using the same
184 method for calculating the CDAI as was used in TRIDENT (Supplemental Methods).
185
186 **Number of subjects**: The sample size calculation in the TRIDENT protocol specified 50
187 subjects per arm. This study analyzed 56 patients.
188
189 **Endpoints**:
190
191 Endpoints included the mean reduction in CDAI at week 12 (TRIDENT primary endpoint) and
192 week 24. Of note, subjects in TRIDENT who entered the study on glucocorticoids were required
193 to remain on them during the induction period. Because real-world clinical practice involves
194 tapering these medications earlier, steroid use and steroid-free clinical remission (CDAI ≤ 150)
195 at weeks 12 and 24 were also included as efficacy endpoints.

196
197 Time windows were used to approximate the true week 12 (weeks 10-14) and week 24 (weeks
198 20-28) relative to the date of ustekinumab initiation. These windows decided upon and fixed a
199 priori, guided by prior work[4].
200
201 Manual review was used to abstract PRO3 elements corresponding to these time windows, and
202 informatics-based criteria were used for the non-PRO3 elements of the CDAI. A second model
203 using *MissForest* was used to impute any missing values across time. These data were then
204 analyzed to estimate the efficacy of ustekinumab according to the above endpoints.
205
206 **Safety**: Safety was not assessed. No incidental findings of possible adverse drug reactions
207 were identified.
208
209 **Statistics**: This was an estimation study; no statistical hypotheses were tested. Binary
210 outcomes are reported numerically and as a proportion. Numeric outcomes are reported by the
211 mean and standard error. Statistical computing was performed in *R*.
212
213 **Ethics/Compliance**: This retrospective study was approved by the UCSF Institutional Review
214 Board (#20-31760).
215
216 **RESULTS**:
217
218 In this study, we used a combination of informatics methods and manual review to identify a
219 real-world cohort with Crohn's disease who met the eligibility criteria of TRIDENT and were
220 treated with ustekinumab. From this cohort, we abstracted and analyzed their post-treatment
221 outcomes according to a number of endpoints including the TRIDENT primary endpoint.
222
223 **Cohort identification**:
224
225 The cohort selection process is outlined in Figure 1, and further described according to the
226 phase of the study.
227
Phases 1 and 2: At the time of our EHR database query (April 2020), 736 patients were
identified as having an ustekinumab medication order and a Crohn's disease diagnosis code.
These records were then manually screened according to the study eligibility criteria. 526
patients failed to meet at least one TRIDENT eligibility criterion. These included the presence of
a low baseline CDAI (prevention of post-operative Crohn's recurrence), as well as the initiation
of steroids to treat active disease while awaiting ustekinumab induction.
234
Phase 3: PRO3 elements were manually abstracted at timepoints ranging from -16 to 0 weeks
relative to the date of ustekinumab initiation. An analysis of data availability according to
differently sized time windows at baseline supported the use of a 12-week window (Figure 2).
Data was commonly missing at time points close to the date of ustekinumab induction, reflecting
gaps of time between clinic visits where treatments were decided upon and the patient receipt of
intravenous ustekinumab. When clinic visits occurred, we found that all three PRO elements
tended to be documented together. These were more commonly available than lab testing such
as c-reactive protein.
243
Phase 4: Non-PRO3 elements were abstracted by manual and informatics-based approaches
on a sample of the still eligible cohort (N=183). The accuracy of CDAI components as
abstracted informatically as well as the CDAI itself was generally high compared to manual

review (Figure 3). The degree of agreement, measured by Pearson's r^2, ranged from 0.91 to
0.96 across timepoints (Table 1, Supplementary Data Tables 1 and 2). This high correlation
appeared to be driven by the fact that for most patients, the major contributor to the total CDAI
came from PRO3 elements, not the other elements ascertained by informatics query.
251
Phase 5: 30% of the cohort was missing at least one PRO3 element at baseline (Table 2). To
handle this missing data and determine cohort membership, we compared two methods
(*MissRanger*, *MissForest*) for performing single imputation. These random forest-based
methods differ in their modes of optimization as well as their final models, which are fit
according to a stochastic process. The two models gave very similar results relevant to the
selection of the baseline cohort and their outcomes (Table 3).
258
Phases 6: The *MissForest* algorithm was used to identify 56 patients meeting all study criteria
(Table 4). Post-baseline PRO3 abstraction was selectively performed in just these patients, and
the previously described informatics algorithm was used to abstract other post-baseline
variables. To handle post-baseline missing data (Table 5), a second imputation model using
MissForest was applied to complete the dataset across timepoints and enable an assessment of
patient outcomes.
265
266 **Efficacy**:
267
268 Ustekinumab was associated with a 95 point mean reduction in the CDAI by week 12, and a
269 133 point reduction by week 24 (N=56; Figure 4, Table 6). The proportions of patients in steroid-
270 free clinical remission were 23% and 34% at Weeks 12 and 24 respectively. 38% of the cohort
271 had been using steroids at the baseline timepoint. Out of the cohort of 56, 7 (13%) and 9 (16%)
272 remained on steroids at weeks 12 and 24 respectively (Table 7).
273
274 **DISCUSSION**:
275
In this pilot study, we used a combination of manual review, EHR data informatics, and
imputation modeling to derive a method for creating external control arms for Crohn's disease.
We applied this method to derive a real-world cohort resembling the ustekinumab arm in
TRIDENT, a concurrent phase 2b trial. We found that algorithms utilizing EHR structured data
were accurate at ascertaining the CDAI (both components and in aggregate) and may be a
favorable alternative to manual review for non-PRO3 components. We found a substantial
amount of missing data in the context of retrospective use for this study design. However, our
results suggested that different imputation models may be equivalent in their impacts on cohort
definition and outcome measurement. Lastly, this observational cohort appeared to demonstrate
a plausible improvement in disease activity by several measures, consistent with the well-
established efficacy of ustekinumab[6].
287
288 Interest in external control arm studies has continued to grow in recent years. This has directly
289 followed from several trends: 1) the increasing availability of large clinical datasets such as from
290 medical claims and EHRs, 2) advances in methods for organizing and extracting information
291 from these data, 3) the large and rising costs of randomized trials[7], 4) increasingly favorable
292 attitudes by regulators towards their use[2].
293
294 If done well, these studies have the potential to transform the way we generate clinical
295 evidence. They can be used to inform the safety and efficacy of existing therapies, as well as
296 new ones by indirect comparison. They may also help answer questions about comparative

297 effectiveness, cost-benefits, and precision medicine, particularly in cohorts who might not have
298 been studied in registrational trials.
299
300 Despite this potential, our pilot study underscores several important differences between this
301 variety of retrospective research and their prospective counterparts. It is more difficult to create
302 a high-quality external control arm for protocols that 1) specify exact study visit timing, 2)
303 prioritize specific outcome measurements that are not commonly obtained in ordinary practice,
304 and 3) constrain what treatments a patient may or may not receive (deviating from clinical care).
305
306 The principal limitation of our approach to creating an external control arm was missing data.
307 This problem can be understood as the natural consequence of retrospective deviation from
308 prospective study design in each of these three ways.
309
310 **Study Timing**:
311
The timing of real-world clinic visits follows clinical necessity as well as the individual
preferences of providers and patients. It is not uncommon for patients to have one clinic visit
that determines the need to start a new therapy, and another to evaluate treatment response.
Delays between the decision to start treatment and the receipt of treatment in the real-world
essentially guarantees missing data at the study visit equivalent of week 0. These delays are
particularly magnified in IBD, where patients with active disease commonly need expensive
biologics that often require payor authorization and scheduling of infusions.
319
320 This situation is similar at the time of follow-up. The precise timing of a follow-up visit can differ
321 based on several factors, including provider availability, patient preferences, and even what
322 drug a patient receives (which in turn informs the most reasonable time to expect a response).
323
Our study attempted to overcome these differences. We noted the high presence of missing
clinic visits at week 0, and therefore used an empirical calibration approach to identify the time
window for estimating a patient's actual CDAI at the time of ustekinumab induction. We use
predefined windows of ± 2 and 4 weeks for the outcome assessment for similar reasons, to
avoid the retrospective miscalibration of clinic visit timings with that of TRIDENT. Future studies
are needed to explore the use of other patient-interactive technologies, such as timed patient
surveys embedded into EHR systems, to better address this limitation.
331
332 **Outcome measures**:
333
334 We found that the informal capture of clinical data can deviate substantially from that of
335 common clinical trial instruments. The CDAI requires a significant amount of data collection
336 across a wide variety of domains – PROs, vitals, laboratories, and extraintestinal diagnoses. It
337 also requires week-long symptom diaries. Unsurprisingly, the CDAI has had poor uptake in
338 actual clinical practice. This was a large driver of missing data in this study.
339
Our findings suggest substantial potential for simplifying these indices, or more generally,
approaches to better align them to the realities of real-world practice. A large part of the reason
why our algorithms were as accurate as they were for ascertaining the CDAI was because of
class imbalance. That is, most patients did not have any EHR-based evidence for extraintestinal
manifestations, and thus their CDAIs were strongly driven by the PROs (all of which were
abstracted manually). A further simplification of the PROs from multi-level ordinal variables to
even a binary variable might make for a good tradeoff between precision and suitability for

routine clinical capture. Future work is needed to develop 'real-world ready' instruments that
maintain responsiveness and validity.
349
350 **Constrained treatments**:
351
The final point, getting at the heart of the difference between clinical care and controlled studies,
resulted in a different kind of missing data problem: one of diminished sample size rather than
missing values. Although we began this study with 736 potential candidates, we excluded about
75% of this population after sequentially applying the major eligibility criteria used to screen
subjects in TRIDENT. This study was not designed to measure what proportion of candidates
were excluded by different criteria. We applied a 'greedy' selection approach (eliminating
candidates at the earliest evidence of disqualification) to avoid the labor of otherwise capturing
7,360 data points (10 non-CDAI eligibility criteria).
360
However, our impression was that many patients were disqualified due to changes in therapy
during the washout period prior to the date of ustekinumab induction. This of course is quite
natural: patients with active Crohn's disease who are under clinical care are highly likely to
undergo changes in treatment, whether rapid transitions from prior treatment to new ones, or
the addition of adjunctive/bridging agents like steroids. This was our reason for removing the
biologic washout requirement as an eligibility criterion in this study.
367
This misalignment between experiments designed to measure treatment effects and clinical
practice designed to treat patients results in a significant loss in study efficiency. One solution
might involve using larger clinical datasets, to find many more of those rare symptomatic
patients who ordinarily would have been treated but by chance were not. However, this
approach may increase the risks of unmeasured confounding and residual bias. A potentially
better solution would be that of an EHR-enabled registry. The use of phenotyping algorithms to
screen patients prior to manual review might be a more cost-effective way to efficiently recruit
patients, guarantee the timing and capture of relevant data, and involve more under-
represented patients in studies that culminate in practice-changing evidence.
377
Strengths of this study include the use of predefined chart review protocol, validation of
algorithms against that of manual review, sensitivity analyses to explore the effects of various
design decisions on outcomes, the release of our raw data and code, and the identification of
treatment effects that are broadly consistent the literature. Weaknesses as described above
pertain primarily to missing data and the resulting inability to make stronger inferences about
treatment effectiveness.
384
385 In conclusion, we have piloted an approach for performing an external control arm study in
386 Crohn's disease. Future studies are needed to improve data capture and bridge the gap
387 between retrospective and prospective clinical research.
388

389 **ACKNOWLEDGEMENTS**: The authors thank Jennifer Creasman, UCSF Academic Research
390 Services, and Clinical Data Research Consultation services for clinical informatics support.

391
392 **DATA SHARING PLAN**: The clinical data used in this study were deidentified to comply with
393 US Department of Health and Human Services 'Safe Harbor' guidance and applicable laws and
394 regulations concerning privacy and/or security of personal information. A deidentified table
395 containing abstracted data and accompanying code have been made available for public use in
396 the supplementary data file accompanying this manuscript.
397

REFERENCES:

1. Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. *J Clin Invest.* 2020;130(2):565-574. doi:10.1172/JCI129197

2. Office of the Commissioner. Framework for FDA's Real-World Evidence Program. FDA. Published December 1, 2018. Accessed July 19, 2021. https://www.fda.gov/media/120060/download

3. Graterman S, Suryaprakash S, Smith B, Rodriguez A. Transforming Clinical Trials with Real-World Evidence. BCG Global. Published February 11, 2021. Accessed July 19, 2021. https://www.bcg.com/publications/2021/synthetic-control-arms-changing-clinical-trials

4. Rudrapatna VA, Glicksberg BS, Butte AJ. Utility of routinely collected electronic health records data to support effectiveness evaluations in inflammatory bowel disease: a pilot study of tofacitinib. *BMJ Health Care Inform.* 2021;28(1):e100337. doi:10.1136/bmjhci-2021-100337

5. Janssen Research & Development, LLC. *A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of JnJ-64304500 in Subjects With Moderately to Severely Active Crohn's Disease.* clinicaltrials.gov; 2021. Accessed July 18, 2021. https://clinicaltrials.gov/ct2/show/NCT02877134

6. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med.* 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773

7. Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. *JAMA Intern Med.* 2018;178(11):1451-1457. doi:10.1001/jamainternmed.2018.3931

FIGURE LEGENDS:

Figure 1: Study flow diagram. 736 patient records were screened for inclusion, 56 records met all study criteria. *: Informatically-censored patients at unique risk for re-identification or who withdrew consent for EHR-based research.

Figure 2: Impact of different definitions for the baseline time period on variable availability. These results correspond to the 183 patients who were not excluded by non-CDAI related study criteria. All of these patient records underwent manual review to ascertain the presence of PROs occurring during the 16 week period prior to the first dose of ustekinumab (week 0). The blue dotted line corresponds to the cut point (12 week lookback) that was selected following a visual review of the trends depicted here.

Figure 3: Comparison of total CDAI as computed using CDAI elements ascertained informatically vs manually. The y-axis corresponds to the CDAI calculated by database query of non-PRO3 elements. The x-axis corresponds to the CDAI calculated by manual abstraction.

Figure 4: Change in CDAI over time. Thin lines correspond to individual CDAI trajectories over time. These are colored turquoise if the patient had a history of biologic intolerance or refractoriness at the time of ustekinumab induction and is colored red otherwise. At each timepoint, closed circles correspond to the use of steroids at a given point of time, open circles otherwise. The thicker blue line depicts the results of LOESS regression.

447 **TABLES**:
448
449 **Table 1: Comparison of total CDAI as computed using CDAI elements ascertained**
450 **informatically vs manually**. All results correspond to the results of manual abstraction by one
451 chart reviewer (45 patients).
452

Time	Mean Absolute Error	Pearson's r^2	Steroid-free Remission (manual)	Steroid-free Remission (informatics)
Baseline	13	0.96	0/14	0/14
Week 12	12	0.93	5/14	6/13
Week 24	17	0.91	6/14	5/13

453
454 **Table 2: Characterization of missing PRO3 elements at baseline**. Proportions correspond to
455 the 183 patients who met all eligibility criteria prior to application of the baseline CDAI
456 requirement.
457

Variable	Missing data
Abdominal Pain	27%
Diarrhea	30%
Wellbeing	20%

458
459 **Table 3: Comparison of the results of two imputation models**. Imputation models were
460 applied to all of the otherwise eligible patients (less the baseline CDAI requirement) that had
461 been assigned to one chart abstractor (45 patients).
462

Measure	Count/Proportion (MissForest)	Count/Proportion (MissRanger)
Patients with baseline CDAIs within range (220-450)	12/45 (27%)	13/45 (29%)
Patients in remission (CDAI ≤ 150) at week 12 among those with within range baseline CDAIs	5/12 (42%)	5/13 (38%)
Patients in remission (CDAI ≤ 150) at week 24 among those with within range baseline CDAIs	5/12 (42%)	5/13 (38%)

463
464 **Table 4: Characterization of the Study Cohort**. *: Reported as median, other continuous
465 variables reported as mean ± standard deviation.
466

	UCSF External Control Arm (N=56)
Age in years	34 ± 14
Female Sex	59%
Disease Duration	10 ± 11
C-Reactive Protein*	12.3
History of Biologic	89%

Intolerance or Refractoriness	
Disease Location:	
• Ileal	13%
• Ileocolonic	52%
• Colonic	30%
• Other	5%
Baseline CDAI	305 ± 51
Baseline steroid use	38%

Table 5: Characterization of missing PRO3 elements across all time periods. Proportions correspond to all 56 members of the external cohort.

Variable	Time	Missing data
Abdominal Pain	Baseline	25%
Diarrhea	Baseline	27%
Wellbeing	Baseline	13%
Abdominal Pain	Week 12	59%
Diarrhea	Week 12	77%
Wellbeing	Week 12	46%
Abdominal Pain	Week 24	61%
Diarrhea	Week 24	66%
Wellbeing	Week 24	43%

Table 6: Efficacy Endpoints

Outcome	Numerical Result [Mean ± SE, N/D (%)]
CDAI Reduction by Week 12	95 ± 13
CDAI Reduction by Week 24	133 ± 11
Proportion in steroid-free remission (CDAI ≤ 150) at Week 12	13/56 (23%)
Proportion in steroid-free remission (CDAI ≤ 150) at Week 24	19/56 (34%)

Table 7: Steroid use across timepoints

Time	Proportion (%)
Baseline	21/56 (37%)

Week 12	7/56 (13%)
Week 24	9/56 (16%)

Ustekinumab Order
+ IBD Diagnosis Code
736

526 excluded
27 with censored data*

Baseline CDAI measured
Other study criteria met
183

127 with a CDAI < 220 or > 450

Study Cohort
56